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Background. Stereotactic core-needle biopsies (SCNBs) are a reliable alternative to surgical biopsy for microcalcifications. The positive 
predictive value (PPV) of SCNB has been shown to be reproducible in several studies using the Breast Imaging Reporting and Data System 
(BIRADS) classification, which is the current gold standard in mammographic reporting. At this stage, no study has been done in KwaZulu-
Natal to assess local outcomes against BIRADS. The current standard of care utilises vacuum-assisted breast biopsy, but is not available 
in a resource-constrained environment such as ours. The need, therefore, is for constant evaluation of existing practice to ensure that it is 
optimised for the challenges and limitations facing local radiologists.
Objective. To assess the PPV of SCNB in Addington Hospital, and to compare it with that of BIRADS.
Material and methods. Mammographically detected lesions were assigned to 3 categories: benign, indeterminate and suspicious. A 
retrospective review of 67 SCNBs was performed for lesions falling within the suspicious category, and the PPV and rates of ductal 
carcinoma in situ (DCIS) were determined.
Results. Our study demonstrated a PPV of 20.9%. This correlated well with international studies for BIRADS 4 and 5 lesions. DCIS 
accounted for 21.4% of detected malignancies, which is in keeping with current literature.
Conclusion. Despite resource limitations, local outcomes were comparable with those of BIRADS. Given our fairly general categorisation 
of lesions, however, it should be emphasised that BIRADS allows better organisation, consistency and clarity in breast imaging reporting, 
as well as accurate data comparison between centres facing limitations similar to our own. 
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The Breast Imaging Reporting and Data System (BIRADS) Lexicon was 
developed in 1985 and is currently in its 4th edition. Its introduction 
acknowledged the need for a standardised system of reporting and 
risk stratification, to aid in predicting the probability of malignancy 
in relation to mammographically identified lesions. To date, it has 
proven to be an accurate predictor of malignancy, depending on 
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the category to which mammographic lesions are assigned. As such, 
BIRADS has been adopted by a large number of mammography 
centres throughout the world.
However, many centres in South Africa (SA), including ours, have 
been slow to embrace BIRADS, even though it is part of the standard 
curriculum in all universities. The reasons for this are not completely 
clear, but a common view is that BIRADS is limited in advising how 
descriptive findings used in the BIRADS Lexicon should be linked 
to the final BIRADS assessment categories.[1] Furthermore, data 
are limited on the prospective classification of microcalcifications 
according to the lexicon.[1]
Addington Hospital typically performs 1 500 - 2 000 mammography 
examinations per year. Until early 2011, the mammography team 
consisted of a part-time radiologist and 2 full-time mammography-
accredited radiographers. Owing to limited resources and long 
waiting lists, our focus has been on high-risk patients and diagnostic 
mammography in symptomatic patients. Obtaining stereotactic 
biopsies is time-consuming and limits the number of examinations 
that can be scheduled per day, thus increasing patient waiting times for 
mammography. An assessment of our current practice was therefore 
deemed necessary to ascertain whether we are performing enough 
biopsies as benchmarked against current international standards, 
and whether our results warranted increased patient waiting times. 
Furthermore, we thought it imperative to ascertain the impact on 
standard of care of not using BIRADS.
The classic signs of malignancy are spiculated masses and linear/
branching calcifications. However, less than 20% of non-palpable 
breast cancers present as a spiculated mass.[2] Subtle signs include focal 
architectural distortion, other calcifications, developing densities, 
single dilated ducts and asymmetric areas of increased density when 
compared with the contralateral breast. Notably, up to one-third of 
non-palpable breast cancers can present with calcifications alone,[2] 
which further highlights the importance of accurate analysis of 
microcalcification patterns.
The above descriptors are generally agreed to be the most accurate 
predictors of malignancy, and our unit uses them as standard 
descriptors of lesions. Whereas BIRADS allows fairly accurate 
stratification of patients into risk categories, our unit typically uses 3 
categories that determine the follow-up management strategy: typically 
benign/normal, indeterminate and suspicious. Typically benign/
normal mammograms receive routine follow-up mammograms. The 
indeterminate category consists of those lesions which lack suspicious 
features, but also lack the characteristic benign features/proven 
stability needed to be assigned to the benign/normal category; 
these lesions receive short-term (6-month) mammographic follow 
up. Mammograms deemed suspicious are typically considered for 
stereotactic or ultrasound-guided biopsies.
The primary purpose of this study was to use our current approach to 
assess the correlation between pre-biopsy classification of non-palpable 
mammographically suspicious lesions, and their underlying 
histology, and to compare our positive predictive value with 
existing published data based on BIRADS.
Material and methods
Study design and patients
We retrospectively reviewed stereotactic core-needle biopsies (SCNB) 
performed at Addington Hospital for non-palpable lesions. Only 
lesions not visualised at ultrasound examination were referred for 
stereotactic biopsies. The time period of our review was January 2007 
- June 2011. The study was reviewed and approved by the Biomedical 
Research and Ethics Committee of the University of KwaZulu-Natal, 
while institutional approval was granted by the Addington Hospital 
Ethics Committee.
All mammogram interpretations and biopsies were performed by 
the same highly experienced radiologist (with more than 30 years in 
this sub-speciality). 
The BIRADS categories were not utilised in the reporting of these 
images. All lesions regarded as ‘suspicious’ were biopsied and would, 
had BIRADS been utilised, in all likelihood have corresponded to a 
BIRADS 4, or higher, category. 
Imaging and evaluation
All mammographic examinations were performed on a Performa 
Stereo unit by GE Healthcare utilising a screen-film technique. 
Biopsy samples were obtained using a Bard Magnum Core Biopsy 
Instrument with a 14-gauge, 13 cm needle. Specimen radiography was 
not performed on any of the samples as this facility was not available. 
Instead, a focal mammographic exposure of the area of concern was 
performed at the time of biopsy procedure, using a highly collimated 
beam to assess the lesion following removal of the relevant lesions/
microcalcifications.
Positive mammograms were considered to be those with a positive 
stereotactic biopsy result for carcinoma or with atypical ductal 
hyperplasia. The positive predictive value (PPV) was defined as the 
number of malignant biopsy results divided by the total number of 
biopsies performed.
Results
The women in the study were 40 - 88 years of age (mean age: 
59.3 years ±11.6). A total of 67 SCNBs were performed during 
the specified period. The 67 lesions comprised 33 (49.3%) masses, 
31 (46.3%) microcalcifications, 1 (1.5%) asymmetry and 2 (3%) 
developing densities (Fig. 1).
Histological testing of SCNB specimens demonstrated malignancy 
in 14 (20.9%) biopsies, with 46 (68.7%) specimens showing 
benignancy. In 7 (10.4%) specimens, the pathology report stated 
benign features but questioned whether the specimens were of a 
representative nature (Fig. 2.). Of these 7 patients, 2 underwent 
excisional biopsies, demonstrating an invasive lobular carcinoma 
in 1, and an intraductal papilloma in the other. Of the remaining 
5 cases, 3 were lost to follow-up while the remaining 2 had follow-
up mammograms. Of the 14 malignancies, 9 (64.3%) presented as 
masses/nodules, 3 (21.4%) as microcalcifications, 1 (7.1%) as an 
asymmetry and 1 (7.1%) as a developing density.
DCIS was diagnosed in 3 (21.4%) SCNBs with malignant histology, 
with invasive ductal carcinoma accounting for 11 (78.6%). Results of 
excisional biopsies showed 1 case of invasive lobular carcinoma and 
1 intraductal papilloma.
Discussion
Despite mammography’s high sensitivity (70 - 90%) for the early 
detection of breast cancer, its efficacy is limited by rather poor PPV. [2] 
As a result, stereotactic biopsy has become an indispensable tool in 
the management of mammographically suspicious lesions. Although 
vacuum-assisted breast biopsy is currently considered the standard 
of care in First World settings – particularly for microcalcifications 
– studies have shown SCNB to be highly accurate when used 
appropriately.[3]
From our study, we determined the PPV for suspicious lesions 
to be 20.9%. This finding is similar to that of Mendez et al., who 
demonstrated a PPV of 20% for BIRADS 4 and 5 lesions for breast 
cancer or atypia.[4] 
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Lazarus et al.[5] conclude that sub-
categorisation of suspicious lesions into 4a, 4b 
and 4c is helpful in predicting the likelihood 
of malignancy. In our unit no subcategories 
were assigned, so further risk stratification 
was not possible. Though the PPV of our 
study was comparable with the PPV for 
combined BIRADS 4 and 5 lesions,[4] our 
lack of categorisation is less helpful in terms 
of communicating pre-biopsy malignancy 
risk to referring physicians, patients, etc.
Roth et al.[3] recommend that specimen 
radiography should be performed for all 
stereotactic biopsy specimens, to ensure that 
representative samples of microcalcifications 
are obtained. In our unit, however, specimen 
radiography could not be performed as this 
would necessitate patient movement and 
repositioning, significantly increasing the 
duration of the procedure. Our approach 
involved a highly coned mammographic 
view of the area of concern, following the 
stereotactic procedure, to ensure removal 
of lesions/microcalcifications. Although a 
metallic marker is commonly placed at the site 
of stereotactic biopsy for calcifications, this was 
not available in our setting. However, given the 
smaller calibre of needles used in our series 
than in vacuum-assisted devices, complete 
removal of lesions was less of a concern, 
reducing the need for marker placements.
Invasive breast cancer is classified into 
2 broad subtypes: ductal and lobular 
carcinoma. Invasive ductal carcinoma 
accounts for up to 85% of invasive cancers, 
with lobular carcinoma comprising about 
10 - 15% of all invasive cancers.[6]
Ductal carcinoma in situ (DCIS), which 
is a precursor to invasive ductal carcinoma, 
represents 20 - 25% of malignancy detected 
at mammographic screening. Because most 
DCIS are high-grade, it is recommended 
that suspicious microcalcifications be 
aggressively investigated.[7] Furthermore, 
a strong correlation between rates of 
detection of DCIS and rates of detection 
of small invasive cancers at screen-film 
mammography has been demonstrated.[8] 
In our study, DCIS accounted for 21.4% of 
malignancies identified on SCNB specimens, 
in keeping with current literature.[7] 
Proliferative lesions without atypia, such 
as ductal hyperplasia, carry only a slightly 
increased risk of malignancy. Atypical ductal 
hyperplasia, however, is known to have a 
moderate risk of invasive breast cancer,[9] 
and thus carries with it an indication for 
excisional biopsy. None of our biopsies 
revealed atypical ductal hyperplasia.
Two patients in our sample underwent 
excisional biopsies for suspicious nodules, 
which returned a diagnosis of invasive 
lobular carcinoma in one and a diagnosis 
of an intraductal papilloma in the other. 
The case of invasive lobular carcinoma is 
particularly interesting because initial SCNB 
demonstrated benign findings, although the 
representative nature of the specimen was 
queried. The patient had a routine 6-month, 
12-month and 24-month mammographic 
follow up, which demonstrated stability 
of the nodule that, in line with current 
recommendations, would indicate benignity. 
However, a mammogram performed at 36 
months demonstrated a slight increase in 
size, prompting an excisional biopsy that 
demonstrated invasive lobular carcinoma. 
This finding represented the one false 
negative, confirmed by excision biopsy, in 
the study. The actual false-negative rate for 
SCNB is not known because most studies 
in the literature have not provided the 
rigorous long-term follow-up (at least 2 - 3 
years) required to identify all false-negative 
diagnoses.[10]
Of the other 5 cases falling into the 
nonspecific benign category, 3 were 
lost to follow-up. The remaining 2 
had mammographic follow- ups for 
microcalcifications at 6, 12 and 24 months 
with no interval change. This frequency 
is in keeping with the recommendation 











Fig. 1. The women were 40 - 88 years of age (mean age: 59.3 years ± 11.6 SD).  A total of 67 
SCNB’s were performed during the specified period. The 67 lesions comprised 33 (49.3%) masses, 








Fig. 2. DCIS was diagnosed in 3 (21.4%) SCNBs with malignant histology, with invasive ductal 
carcinoma accounting for 11 (78.6%). Results of excisional biopsies showed 1 case of invasive lobular 
carcinoma and 1 intraductal papilloma
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cases that yield nonspecific benign results at SCNB, and yearly 
screening mammography for cases with specific benign results.[11] 
An alternative to continued mammographic surveillance would have 
been a repeat SCNB with an 11-gauge, vacuum-assisted device, but 
this was not available. 
Limitations
Our study was limited by our SCNB sampling procedure, which did 
not utilise specimen radiography as recommended by Roth et al.3 
For logistical reasons, we performed a repeat focal mammographic 
view to assess biopsy of relevant lesions. This approach is clearly 
suboptimal as it increases patient exposure during the examination. 
It also fails to accurately comment on the representative nature of 
microcalcification specimens in particular, for which specimen 
radiography is mandatory. However, this has proven to be the only 
viable option in view of resource limitations: at present, performing 
specimen radiography would require either a second mammography 
unit, a cabinet X-ray system for point-of-care specimen radiography 
or an interruption in the procedure to allow for a specimen radiograph 
to be taken. Given our financial and time constraints, none of these 
options was viable at the time.
A further limitation was that all mammograms were read by a 
single reader, albeit one with 30 years’ experience. The data are 
therefore not necessarily generalisable to everyday practice, especially 
where relatively junior radiologists are concerned. This further 
emphasises the need for a more universal system, such as BIRADS, 
which addresses these factors.
The data set of 67 biopsies was relatively small. A larger sample 
would definitely add greater statistical value to the findings, although 
the current results in addition to the literature, do provide a good 
reference point for future modifications in our unit.
A final limitation was the lack of rigorous follow-up in those 
patients with benign histology on core-needle biopsy. As follow-up 
in our local setting is and will continue to be a major challenge, the 
incidence of non-benign lesions missed on initial SCNB remains an 
ongoing concern at present and into the foreseeable future.
Conclusion
The absence of subcategorisation in the system used in our unit had 
no detrimental effect on definitive patient management, as our PPV 
was comparable with studies employing BIRADS. This consistency 
demonstrates that optimal outcomes can be achieved despite resource 
constraints, which are becoming increasingly prevalent.
A significant shortfall of our approach is its lack of the standard 
language and action-oriented approach to breast imaging reporting, 
which is one of the primary goals of BIRADS. The BIRADS Lexicon 
was specifically devised to ensure that commonly used terms such 
as ‘pleomorphic’, ‘coarse heterogeneous’ and ‘spiculated’ would have 
the same meaning regardless of the radiologist interpreting the study. 
The final assessment categories were also developed to ensure a 
conclusive and clear plan of action. 
Although our overall outcomes were relatively similar to BIRADS, 
failure to adopt the latter could isolate a breast centre from mainstream 
mammography practice and compromise its ability to meaningfully 
engage other role players on a common platform. Therefore, it is highly 
recommended that BIRADS not only be taught but also practised.
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